NCT05344820

Brief Summary

The aim of this study is to determine the effect of mandala application on fatigue, quality of life, rumination and alexithymia in cancer patients receiving chemotherapy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for not_applicable cancer

Timeline
Completed

Started May 2022

Shorter than P25 for not_applicable cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 18, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 25, 2022

Completed
24 days until next milestone

Study Start

First participant enrolled

May 19, 2022

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

June 22, 2022

Status Verified

June 1, 2022

Enrollment Period

8 months

First QC Date

April 18, 2022

Last Update Submit

June 19, 2022

Conditions

Keywords

cancerChemotherapy EffectFatigueQuality of LifeRuminationAlexithymia

Outcome Measures

Primary Outcomes (2)

  • level of quality of life

    Level of quality of life as assessed by the Quality of Life Scale for the Treatment and Research of Cancer (min:0, max:100,with higher values indicating a higher functioning in functional scales and an increased presence of symptoms in symptom scales)

    1 week

  • level of fatigue

    level of fatigue assessed by the Piper Fatigue Scale (min:0, max, 100, higher values means higher fatigue)

    1 week

Secondary Outcomes (2)

  • level of alexithymia

    1 week

  • level of rumination

    1 week

Study Arms (2)

Mandala Intervention

EXPERIMENTAL

To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.

Behavioral: Art based mandala

Control

NO INTERVENTION

No intervention will be applied to the control group

Interventions

To the experimental group; Mandala practice will be done for 2 hours, once a week for 8 weeks.

Mandala Intervention

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years or older
  • Conscious and no communication problems
  • Being literate
  • Having a cancer diagnosis
  • Receiving chemotherapy treatment (planned to continue treatment for 8 more weeks)
  • Willing to participate in our study voluntarily

You may not qualify if:

  • Not being willing to participate in the research
  • Desire to leave the study at any time
  • Deterioration of compliance with the working criteria during the time of the study,
  • Those who do not participate in up to four mandala applications during the study period
  • Those who cannot use a pen
  • Those with a diagnosis of psychiatric and neurological disease
  • Patients who are scheduled for drug intervention, radiotherapy, surgery other than chemotherapy within 8 weeks

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sultan Abdülhamid Training and Research Hospital

Üsküdar, Istanbul, 34660, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

NeoplasmsFatigueRumination SyndromeAffective Symptoms

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsGastrointestinal DiseasesDigestive System DiseasesFeeding and Eating DisordersMental DisordersBehavioral SymptomsBehavior

Study Officials

  • Elif Yıldırım Ayaz, M.D.

    Sultan Abdülhamid Training And Research Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Elif Yıldırım Ayaz, M.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 18, 2022

First Posted

April 25, 2022

Study Start

May 19, 2022

Primary Completion

December 31, 2022

Study Completion

December 31, 2022

Last Updated

June 22, 2022

Record last verified: 2022-06

Data Sharing

IPD Sharing
Will not share

Locations